The drug is now approved for treating people with an LVEF of at least 40%, with or without chronic kidney disease.

The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.

Tempus AI, Inc. (NASDAQ:TEM) saw its stock rise 3% on Wednesday following the announcement that the company obtained 510(k) ...

Following priority review, the FDA approved Kerendia for the treatment of patients with heart failure with left ventricular ejection fraction (LVEF) ≥40%.

Following priority review, the U.S. Food and Drug Administration approved Bayer's Kerendia (finerenone) for the treatment of ...

The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced.

Kerendia was originally approved in July 2021 to reduce cardiovascular and kidney complications in patients with chronic ...

Finerenone gained FDA approval for heart failure treatment, showcasing significant benefits in reducing cardiovascular events ...

Accurately identifying patients with Right Ventricular Dysfunction (RVD) is critical for timely diagnosis and treatment, yet it remains a significant challenge in clinical practice due to the ...

BACKGROUND: Fontan circulatory failure (FCF) is a chronic state in palliated single ventricle heart disease with high morbidity and mortality rates, including heart failure, multisystem end-organ ...

Mesoblast shows promise with FDA progress and a strong pipeline, but limited data and execution risks persist. Learn why MESO ...